These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
415 related articles for article (PubMed ID: 25306392)
21. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. Von Hoff DD; LoRusso PM; Rudin CM; Reddy JC; Yauch RL; Tibes R; Weiss GJ; Borad MJ; Hann CL; Brahmer JR; Mackey HM; Lum BL; Darbonne WC; Marsters JC; de Sauvage FJ; Low JA N Engl J Med; 2009 Sep; 361(12):1164-72. PubMed ID: 19726763 [TBL] [Abstract][Full Text] [Related]
22. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Kim J; Aftab BT; Tang JY; Kim D; Lee AH; Rezaee M; Kim J; Chen B; King EM; Borodovsky A; Riggins GJ; Epstein EH; Beachy PA; Rudin CM Cancer Cell; 2013 Jan; 23(1):23-34. PubMed ID: 23291299 [TBL] [Abstract][Full Text] [Related]
23. Activating Smoothened mutations in sporadic basal-cell carcinoma. Xie J; Murone M; Luoh SM; Ryan A; Gu Q; Zhang C; Bonifas JM; Lam CW; Hynes M; Goddard A; Rosenthal A; Epstein EH; de Sauvage FJ Nature; 1998 Jan; 391(6662):90-2. PubMed ID: 9422511 [TBL] [Abstract][Full Text] [Related]
25. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma. Proctor AE; Thompson LA; O'Bryant CL Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609 [TBL] [Abstract][Full Text] [Related]
26. Molecular biology of basal and squamous cell carcinomas. Emmert S; Schön MP; Haenssle HA Adv Exp Med Biol; 2014; 810():234-52. PubMed ID: 25207369 [TBL] [Abstract][Full Text] [Related]
27. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial. Dessinioti C; Plaka M; Stratigos AJ Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979 [TBL] [Abstract][Full Text] [Related]
28. Expression of sonic hedgehog signal transducers, patched and smoothened, in human basal cell carcinoma. Tojo M; Mori T; Kiyosawa H; Honma Y; Tanno Y; Kanazawa KY; Yokoya S; Kaneko F; Wanaka A Pathol Int; 1999 Aug; 49(8):687-94. PubMed ID: 10504535 [TBL] [Abstract][Full Text] [Related]
29. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity. Zhang H; Sun Z; Liu Z; Song C Future Med Chem; 2018 Dec; 10(24):2855-2875. PubMed ID: 30557039 [TBL] [Abstract][Full Text] [Related]
31. RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors. Zhao X; Ponomaryov T; Ornell KJ; Zhou P; Dabral SK; Pak E; Li W; Atwood SX; Whitson RJ; Chang AL; Li J; Oro AE; Chan JA; Kelleher JF; Segal RA Cancer Res; 2015 Sep; 75(17):3623-35. PubMed ID: 26130651 [TBL] [Abstract][Full Text] [Related]
32. Smoothened inhibitors in the treatment of advanced basal cell carcinomas. Kunstfeld R Curr Opin Oncol; 2014 Mar; 26(2):184-95. PubMed ID: 24469022 [TBL] [Abstract][Full Text] [Related]
33. Targeting the hedgehog pathway to treat basal cell carcinoma. Geeraert P; Williams JS; Brownell I J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945 [TBL] [Abstract][Full Text] [Related]
34. Hedgehog Pathway Inhibition. Sekulic A; Von Hoff D Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418 [TBL] [Abstract][Full Text] [Related]
35. PTCH1 and SMO gene alterations in keratocystic odontogenic tumors. Sun LS; Li XF; Li TJ J Dent Res; 2008 Jun; 87(6):575-9. PubMed ID: 18502968 [TBL] [Abstract][Full Text] [Related]
36. All-trans-retinoic acid antagonizes the Hedgehog pathway by inducing patched. Busch AM; Galimberti F; Nehls KE; Roengvoraphoj M; Sekula D; Li B; Guo Y; Direnzo J; Fiering SN; Spinella MJ; Robbins DJ; Memoli VA; Freemantle SJ; Dmitrovsky E Cancer Biol Ther; 2014 Apr; 15(4):463-72. PubMed ID: 24496080 [TBL] [Abstract][Full Text] [Related]
37. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Kool M; Jones DT; Jäger N; Northcott PA; Pugh TJ; Hovestadt V; Piro RM; Esparza LA; Markant SL; Remke M; Milde T; Bourdeaut F; Ryzhova M; Sturm D; Pfaff E; Stark S; Hutter S; Seker-Cin H; Johann P; Bender S; Schmidt C; Rausch T; Shih D; Reimand J; Sieber L; Wittmann A; Linke L; Witt H; Weber UD; Zapatka M; König R; Beroukhim R; Bergthold G; van Sluis P; Volckmann R; Koster J; Versteeg R; Schmidt S; Wolf S; Lawerenz C; Bartholomae CC; von Kalle C; Unterberg A; Herold-Mende C; Hofer S; Kulozik AE; von Deimling A; Scheurlen W; Felsberg J; Reifenberger G; Hasselblatt M; Crawford JR; Grant GA; Jabado N; Perry A; Cowdrey C; Croul S; Zadeh G; Korbel JO; Doz F; Delattre O; Bader GD; McCabe MG; Collins VP; Kieran MW; Cho YJ; Pomeroy SL; Witt O; Brors B; Taylor MD; Schüller U; Korshunov A; Eils R; Wechsler-Reya RJ; Lichter P; Pfister SM; Cancer Cell; 2014 Mar; 25(3):393-405. PubMed ID: 24651015 [TBL] [Abstract][Full Text] [Related]
38. Repression of smoothened by patched-dependent (pro-)vitamin D3 secretion. Bijlsma MF; Spek CA; Zivkovic D; van de Water S; Rezaee F; Peppelenbosch MP PLoS Biol; 2006 Jul; 4(8):e232. PubMed ID: 16895439 [TBL] [Abstract][Full Text] [Related]
39. Inhibition of smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis. Athar M; Li C; Tang X; Chi S; Zhang X; Kim AL; Tyring SK; Kopelovich L; Hebert J; Epstein EH; Bickers DR; Xie J Cancer Res; 2004 Oct; 64(20):7545-52. PubMed ID: 15492281 [TBL] [Abstract][Full Text] [Related]
40. Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma. Brinkhuizen T; Reinders MG; van Geel M; Hendriksen AJ; Paulussen AD; Winnepenninckx VJ; Keymeulen KB; Soetekouw PM; van Steensel MA; Mosterd K J Am Acad Dermatol; 2014 Nov; 71(5):1005-8. PubMed ID: 25199678 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]